Supernus to Present at Piper Jaffray Healthcare Conference in December
ROCKVILLE, Md., Nov. 21, 2013 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals,
Inc. (Nasdaq:SUPN), a specialty pharmaceutical company, today announced that
the Company's management will present an overview of the Company at the Piper
Jaffray Healthcare Investor Conference.
Presentation Date: Wednesday, December 4
Place: The New York Palace, New York, NY
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc. is a specialty pharmaceutical company focused
on developing and commercializing products for the treatment of central
nervous system, or CNS, diseases. The Company has two marketed products for
epilepsy, Oxtellar XR^TM (extended release oxcarbazepine), and Trokendi XR^TM
(extended release topiramate). The Company is also developing several
product candidates in psychiatry to address large market opportunities in ADHD
including ADHD patients with impulsive aggression. These product candidates
include SPN-810 for impulsive aggression in ADHD and SPN-812 for ADHD.
CONTACT: Jack A. Khattar, President and CEO
Gregory S. Patrick, Vice President and CFO
Supernus Pharmaceuticals, Inc.
Tel: (301) 838-2591
Press spacebar to pause and continue. Press esc to stop.